Contact this trialFirst, we need to learn more about you.
Corticosteroid
CORT108297 for Alzheimer's Disease
Recruiting0 awardsPhase 2
Baltimore, Maryland
This trial is examining if a stress-mediation pathogenesis of Alzheimer's disease is a possible target for intervention in individuals at risk for the disease. The study is a 2-week, placebo-controlled crossover study of the effects of the selective glucocorticoid receptor antagonist, CORT108297, on cognitive test performance in 26 individuals with mild cognitive impairment (MCI) due to AD and in 26 cognitively normal individuals with an increased risk for AD.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service